The C-Path Model

C-Path is a pioneer in building and managing successful global, cross-sector consortia. The model through which C-Path’s consortia operate was constructed to overcome challenges in collaborative science, providing a framework for fostering collaboration and shattering existing barriers to data-sharing in clinical trials. A template that future similar organizations will look to for guidance and inspiration, the C-Path model is built around four central components:

  1. A legal framework to establish a “pre-competitive” space for collaboration, i.e., how IP would be protected, and how anti-trust, anti-bribery, and anti-corruption would be carried out. The framework provides the necessary clarity with respect to important issues such as governance, publication rights, confidentiality, and access to information and data.
  2. A secure data-sharing and information platform to support the ongoing efforts of C-Path’s consortia and enable the secure exchange of confidential information and data among consortium members.
  3. Capable leadership in both scientific and project management roles to drive projects toward their primary objectives. By providing such leadership, C-Path creates a culture that supports effective collaboration and manages expectations along the way, preventing distraction from the end goal and reinforcing that all parties are accountable and expected to contribute. This culture allows members to share the benefits of cutting-edge science, drive consensus and publications, and assures the engagement of regulators.
  4. A results-oriented approach is key to ensuring that collaborative engagement and information sharing leads to planned expectations. C-Path identifies specific projects for which there is an unmet need, and, early in the process, develops detailed research plans with specific timelines and deliverables.

Receptivity to the C-Path model continues to grow. Many organizations, including research institutes, foundations, and patient advocates wish to be part of new consortia when they are launched, and organizations now approach C-Path to collaborate, based on C-Path’s existing achievements. By accomplishing what no one organization could do alone, C-Path’s collaborative approach gets results in the form of official regulatory endorsement of novel methodologies and drug development tools.